PMID- 24691423
OWN - NLM
STAT- MEDLINE
DCOM- 20140715
LR  - 20220409
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 110
IP  - 10
DP  - 2014 May 13
TI  - Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical 
      outcome in glioma.
PG  - 2560-8
LID - 10.1038/bjc.2014.162 [doi]
AB  - BACKGROUND: T lymphocyte infiltration has been detected in glioma, although its 
      significance remains unclear. The purpose of the present study was to explore the 
      prognostic value of CD4(+) and CD8(+) tumour-infiltrating lymphocytes (TILs) in 
      glioma, and the prognostic value of infiltrating Forkhead box protein 3 
      (FoxP3(+)) regulatory T cells were also investigated. METHODS: CD4(+), FoxP3(+) 
      and CD8(+) TILs were assessed by immunohistochemical staining of tissue 
      microarray cores from 284 gliomas. Kaplan-Meier analysis and Cox proportional 
      hazards models were used to examine the survival function of these TILs in 90 
      glioblastoma patients. RESULTS: The number of CD8(+) TILs was inversely 
      correlated with tumour grade (P=0.025), whereas the number of CD4(+) TILs was 
      positively correlated with tumour grade (P=0.002). FoxP3(+) TILs were only 
      observed in glioblastomas, but not in low-grade astrocytomas or oligodendroglial 
      tumours. Among patients with glioblastoma, none of CD4(+) TILs, FoxP3(+) TILs and 
      CD8(+) TILs alone was significantly associated with patient prognosis. However, 
      the presence of high CD4(+) and low CD8(+) TIL levels was an independent 
      predictor of poor progress-free survival (multivariate hazard ratio (HR) 1.618, 
      95% confidence interval (CI) 1.245-2.101, P<0.001) and poor overall survival 
      (multivariate HR 1.508, 95% CI 1.162-1.956, P=0.002). Moreover, pseudoprogression 
      was more often found in patients with high CD4(+) TILs and high CD8(+) TILs. 
      CONCLUSIONS: The combination of CD4(+) and CD8(+) TILs is a predictor of clinical 
      outcome in glioblastoma patients, and a high level of CD4(+) TILs combined with 
      low CD8(+) TILs was associated with unfavourable prognosis.
FAU - Han, S
AU  - Han S
AD  - Department of Neurosurgery, The First Hospital of China Medical University, 
      Nanjing street 155, Heping district, Shenyang 110001, China.
FAU - Zhang, C
AU  - Zhang C
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing 100050, China.
FAU - Li, Q
AU  - Li Q
AD  - Department of Pathology, China Medical University, Shenyang 110001, China.
FAU - Dong, J
AU  - Dong J
AD  - Department of Neurosurgery, The First Hospital of China Medical University, 
      Nanjing street 155, Heping district, Shenyang 110001, China.
FAU - Liu, Y
AU  - Liu Y
AD  - Department of Neurosurgery, The First Hospital of China Medical University, 
      Nanjing street 155, Heping district, Shenyang 110001, China.
FAU - Huang, Y
AU  - Huang Y
AD  - Department of Neurosurgery, The First Hospital of China Medical University, 
      Nanjing street 155, Heping district, Shenyang 110001, China.
FAU - Jiang, T
AU  - Jiang T
AD  - Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing 100050, China.
FAU - Wu, A
AU  - Wu A
AD  - Department of Neurosurgery, The First Hospital of China Medical University, 
      Nanjing street 155, Heping district, Shenyang 110001, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140401
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (FOXP3 protein, human)
RN  - 0 (Forkhead Transcription Factors)
SB  - IM
MH  - Adult
MH  - CD4-Positive T-Lymphocytes/*pathology
MH  - CD8-Positive T-Lymphocytes/*pathology
MH  - Central Nervous System Neoplasms/immunology/mortality/*pathology/therapy
MH  - DNA Methylation
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Forkhead Transcription Factors/analysis
MH  - Glioma/immunology/mortality/*pathology/therapy
MH  - Humans
MH  - Immunophenotyping
MH  - Kaplan-Meier Estimate
MH  - Lymphocytes, Tumor-Infiltrating/*pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - T-Lymphocytes, Regulatory/pathology
MH  - Tumor Escape
PMC - PMC4021514
EDAT- 2014/04/03 06:00
MHDA- 2014/07/16 06:00
PMCR- 2015/05/13
CRDT- 2014/04/03 06:00
PHST- 2014/01/20 00:00 [received]
PHST- 2014/03/02 00:00 [revised]
PHST- 2014/03/04 00:00 [accepted]
PHST- 2014/04/03 06:00 [entrez]
PHST- 2014/04/03 06:00 [pubmed]
PHST- 2014/07/16 06:00 [medline]
PHST- 2015/05/13 00:00 [pmc-release]
AID - bjc2014162 [pii]
AID - 10.1038/bjc.2014.162 [doi]
PST - ppublish
SO  - Br J Cancer. 2014 May 13;110(10):2560-8. doi: 10.1038/bjc.2014.162. Epub 2014 Apr 
      1.